Video Experimental Relacionado
Updated: Mar 2, 2026
09:00
Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice
Published on: August 2, 2018
8.7K
Edición de bases terapéutica alivia la miocardiopatía restrictiva
Chong Chang1, Xiulin Zhang2, Xiaoqi Fan3
1College of Life Sciences, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Gene Expression, School of Medicine, Westlake University, Hangzhou, Zhejiang 310030, China.
Cell reports. Medicine
|February 28, 2026
Resumen
La edición de bases de adenina (ABE) corrigió con éxito una mutación que causa miocardiopatía restrictiva (MRC) en ratones. Este enfoque de terapia génica mejoró la función cardíaca, ofreciendo esperanza para el tratamiento de afecciones cardíacas genéticas.
Sus antecedentes:
- La miocardiopatía restrictiva (MRC) es una afección cardíaca grave que altera la función diastólica, a menudo causada por mutaciones en las proteínas del sarcómero.
- Las mutaciones en el gen TNNI3, como la p.R192H, son importantes impulsores genéticos de la MRC, especialmente en casos pediátricos con malos resultados.
Conclusiones:
- La edición de bases de adenina demuestra potencial terapéutico para la MRC mediante la corrección de mutaciones causales.
- Este estudio apoya la aplicación más amplia de la edición de bases para el tratamiento de miocardiopatías genéticas.
Videos de Conceptos Relacionados
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
658
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
658
01:29Cardiomyopathy V: Interprofessional Care
551
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
551
01:30Cardiomyopathy II: Dilated Cardiomyopathy
675
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
675
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
578
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
578
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:29Cardiomyopathy VI: Nursing Management
408
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
408